ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 0679 • ACR Convergence 2024

    Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

    Rachel Wallwork1, Haomin Hu2, Ami Shah3, Laura Hummers4, John Pauling5, Victoria Flower6, Bambang Parmanto2, Andi Saptono2 and Robyn Domsic7, 1Johns Hopkins University, Towson, MD, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 4Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 5North Bristol NHS Trust, Bristol, United Kingdom, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene.  Despite…
  • Abstract Number: 0782 • ACR Convergence 2024

    30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis

    Sylvia Posso1, Jane Buckner2, Montserrat Anguera3 and Nikhil Jiwrajka4, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3University of Pennsylvania, Philadelphia, PA, 4Hospital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Systemic sclerosis (SSc) is a heavily female-biased systemic autoimmune disease associated with significant morbidity and mortality due to fibrosis of the skin and vital…
  • Abstract Number: 1566 • ACR Convergence 2024

    Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study

    Sumbal Wajid1, Lee Shapiro2, Virginia Steen3, Robyn Domsic4, Paul J. Feustel5 and Swati Mehta6, 1Albany Medical Center, Albany, NY, 2Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, 3Georgetown University School of Medicine, Washington, DC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, 6Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
  • Abstract Number: 1818 • ACR Convergence 2024

    Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin

    Banafsheh Nazari1, Tracy Tabib2, Christina Morse3 and Robert Lafyatis2, 1UPMC-Mercy, Pittsburgh, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh

    Background/Purpose: Our previous single-cell RNA-sequencing study identified two major fibroblast subpopulations in healthy skin biopsies: SFRP2/DPP4 and FMO1/LSP1 fibroblasts¹. Additionally, we discovered that adventitial fibroblasts…
  • Abstract Number: 1977 • ACR Convergence 2024

    Three-dimensional Stereophotogrammetry Has Utility in Tracking Upper Eyelid Involvement and Overall Disease Worsening in Patients with Craniofacial Localized Scleroderma

    Tyler Cepica1, Jennifer Foster2, Priya Sarlashkar2, Rami Hallac3 and Heidi Jacobe2, 1University of Texas Southwestern Medical School, Benbrook, TX, 2The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, 3The University of Texas Southwestern Medical Center, Department of Pastic Surgery, Dallas, TX

    Background/Purpose: Craniofacial localized scleroderma’s (LoS) indolent and subtle course poses challenges in quantifying disease progression. Traditional serial photography and the Localized Scleroderma Cutaneous Assessment Tool…
  • Abstract Number: 2643 • ACR Convergence 2024

    Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis

    Kristina Clark1, Corrado Campochiaro2, Emma Derrett-Smith3, Voon Ong4, Christopher Buckley5 and Christopher Denton6, 1University of Oxford, Oxford, United Kingdom, 2IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 3University College London Division of Medicine, Birmingham, United Kingdom, 4University College London, London, England, United Kingdom, 5Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 6University College London, Northwood, United Kingdom

    Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc).  TGFβ is a key growth factor driving myofibroblast formation in SSc.  The main…
  • Abstract Number: 0682 • ACR Convergence 2024

    Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project

    Alain Lescoat1, Yen Chen2, Susan Murphy3, Nadia Vann2, Neda Kortam2, Rosemary Gedert2, Sue Farrington4, Yannick Allanore5, David Cella6, Lorinda Chung7, Philip Clements8, Christopher Denton9, Francesco Del Galdo10, Oliver Distler11, Monique Hinchcliff12, Michael Hughes13, Laura Hummers14, John Pauling15, Janet Pope16, Virginia Steen17, John Varga2, Peter Merkel18, Maya H. Buch19 and Dinesh Khanna2, and all CRISTAL collaborators, 1CHU Rennes - University Rennes 1, Rennes, France, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Plymouth, MI, 4Scleroderma & Raynaud UK, London, United Kingdom, 5Université Paris Cité, Paris, France, 6Northwestern University, Chicago, IL, 7Stanford University, Woodside, CA, 8United States, Los Angeles, CA, 9University College London, Northwood, United Kingdom, 10University of Leeds, Leeds, United Kingdom, 11Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 12Yale School of Medicine, Westport, CT, 13Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, 14Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 15North Bristol NHS Trust, Bristol, United Kingdom, 16University of Western Ontario, London, ON, Canada, 17Georgetown University School of Medicine, Washington, DC, 18University of Pennsylvania, Philadelphia, PA, 19Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

    Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures available to assess symptoms…
  • Abstract Number: 0785 • ACR Convergence 2024

    Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis

    Elizabeth Caves1, Agrani Dixit1, Anna Jussila2, Vivian Lei3, Hailey Edelman4, Muhammad Hamdan5, Ian Odell5, Monique Hinchcliff6, Radhika Atit7 and Valerie Horsley1, 1Yale School of Medicine, New Haven, CT, 2Stanford Medicine, Stanford, CA, 3University of North Carolina School of Medicine, Chapel Hill, 4Vanderbilt School of Engineering, New Haven, 5Yale School of Medicine, New Haven, 6Yale School of Medicine, Westport, CT, 7Case Western Reserve University College of Arts and Sciences, Cleveland

    Background/Purpose: Resident lipid-filled dermal adipocytes are depleted in both systemic sclerosis (SSc) and scleroderma mouse models, but mechanisms are poorly understood. We undertook studies in mouse…
  • Abstract Number: 1568 • ACR Convergence 2024

    Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study

    Arifa Javed1, Lilit Grigoryan2, Alex Luta3, Sumbal Wajid2, Lee Shapiro4, Virginia Steen5 and Swati Mehta6, 1Albany Medical Center, Rensselaer, NY, 2Albany Medical Center, Albany, NY, 3MedStar Georgetown University Hospital, Rockville, MD, 4Albany Medical College, Stillwater, NY, 5Georgetown University School of Medicine, Washington, DC, 6Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare but life-threatening complication of systemic sclerosis (SSc), characterized by malignant hypertension and acute kidney injury (AKI). Proteinuria when present at the time of…
  • Abstract Number: 1819 • ACR Convergence 2024

    Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis

    Ye Jin Jeong1, Gayathri Guru Murthy1, Gaochan Wang1, Tahia Rahman1 and Benjamin Korman2, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester, Rochester, NY

    Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
  • Abstract Number: 2052 • ACR Convergence 2024

    Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center

    Carmen Secada Gómez1, Diana Prieto-Peña2, Mónica Renuncio-García3, Juan Irure-Ventura4, Marcos Lopez-Hoyos5 and Ricardo Blanco-Alonso6, 1Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 4Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, 5Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, 6Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: In clinical practice, immunoblot assays are being used more frequently as a diagnostic tool for systemic autoimmune rheumatic diseases (SARDs).Our aim was to evaluate the…
  • Abstract Number: 2644 • ACR Convergence 2024

    Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis

    Kimberly Lakin1, Robert Spiera2, John Spivack1, Yaxia Zhang1, Jessica Gordon3 and dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 3Division of Rheumatology, Weill Cornell Medical College, New York, NY, 4Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that fibroblast CD34 is low and alpha-smooth muscle actin (aSMA) is high in severe diffuse cutaneous systemic sclerosis (dcSSc) skin,…
  • Abstract Number: 0689 • ACR Convergence 2024

    Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis

    Silvia Laura Bosello1, Enrico De Lorenzis2, Giacomo De Luca3, Antonio Tonutti4, veronica Batani5, Pier Giacomo Cerasuolo6, Gerlando Natalello7, Lucia Lanzo6, Gabriella Alonzi6, Silvia Fiore6, Stefano Di Murro6, Andrea Zoli6, Valentina Boni6, Riccardo Marano8, Francesca Augusta Gabrielli9, Francesco Del Galdo10, Dan Knight11, Vivek Muthurangu11, Christopher Denton12, Maria De Santis4, Marco Matucci Cerinic5 and Maria Antonietta D'Agostino13, 1Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Catholic University of the Sacred Heart, Roma, Rome, Italy, 3Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, 4Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, 6Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, 8Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Diagnostic Imaging Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, 9Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 10University of Leeds, Leeds, United Kingdom, 11UCL Department of Cardiac MRI, University College London (Royal Free Campus), London, United Kingdom, 12University College London, Northwood, United Kingdom, 13Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy

    Background/Purpose: Cardiac involvement in Systemic Sclerosis (SSc) is widely recognized as heterogeneous and, when clinically evident, it is associated with a poor prognosis. Recently, five…
  • Abstract Number: 0954 • ACR Convergence 2024

    Increased Proliferating Natural Killer Cells Exhibit an Aberrant Pro-Inflammatory Gene Signature in Systemic Sclerosis Patients

    Pietro Bearzi1, Elena Pachera2, Sophie Wagner3, Astrid Hofman4, Lumeng Li4, Laura Much4, Mike Becker5, Kristina Bürki4, Luca Navarini6, Anna-Maria Hoffmann-Vold7, Roberto Giacomelli8 and Oliver Distler9, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3University of Zurich, Schlieren, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 6Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy, 7Oslo University Hospital, Oslo, Norway, 8Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, University of Rome "Campus Bio-Medico", Roma, Italy, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: Recent transcriptomic data suggest a prominent involvement of innate immune cells in the pathogenesis of SSc. In this regard, contrasting data on NK cells…
  • Abstract Number: 1570 • ACR Convergence 2024

    Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

    Sunhwa Kim1, Yingtao Bi2, Vishal Kakkar3, Rebecca Ross4 and Francesco Del Galdo3, 1AbbVie, South San Francisco, CA, 2Abbvie, Worcester, MA, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease with variable clinical presentations and progression rates. Accurate patient stratification is crucial for optimizing treatment strategies.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology